Specific antibody responses against the 2 major subcomponents of EBNA, EBNAl and EBNAZ were evaluated, in order to study whether this serological study was beneficial compared to classical EBV serology. During this investigation, 491 sera, obtained from blood donors and patients with Burkitt's lymph
Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2
✍ Scribed by Kelly, Gemma; Bell, Andrew; Rickinson, Alan
- Book ID
- 109933192
- Publisher
- Nature Publishing Group
- Year
- 2002
- Tongue
- English
- Weight
- 870 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1078-8956
- DOI
- 10.1038/nm758
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The effect of two DNA antagonists (IUDR and Ara C) on EBV‐associated antigens was studied in two BL‐derived carrier culture lines (P3HR‐1 and Onesmas). Both drugs led to an accumulation of the early antigen (EA) from 2% in the untreated to 5–40% in the treated cultures. Ara C blocked th
Epstein-Barr virus (EBV) is a human tumour virus that efficiently growth-transforms primary human B-lymphocytes in vitro. The viral nuclear antigen 2 (EBNA2) is essential for immortalisation of B-cells and stimulates viral and cellular gene expression through interaction with DNA-bound transcription
A new monoclonal antibody bas been used to examine immunohistochemically the expression of the Epstein-Barr virus (EBV)encoded nuclear antigen (EBNA) 1 in virus-associated epithelial lesions. EBNAl was detected in the tumour cell nuclei of 10113 undifferentiated nasopharyngeal carcinomas and of 1011